Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22749221 | 0.88 | CNR2 (0.46) | CNR2L3MBTL1GAAKMT2AGLA | |
| SCHEMBL22749175 | 0.86 | CNR2 (0.47) | CNR2L3MBTL1GAAKMT2AGLA | |
| SCHEMBL19893122 | 0.81 | CNR2 (0.47) | CNR2L3MBTL1GAAKMT2AGLA | |
| SCHEMBL21960946 | 0.75 | CNR2 (0.55) | CNR2L3MBTL1GAAKMT2AGLA | |
| SCHEMBL25796607 | 0.73 | CNR2 (0.53) | CNR2L3MBTL1GAAKMT2AGLA | |
| SCHEMBL21000857 | 0.71 | SMN1; SMN2 (0.50) | CNR2L3MBTL1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL4443917 | 0.71 | CNR2 (0.47) | CNR2L3MBTL1GAAKMT2AGLA | |
| SCHEMBL17923514 | 0.71 | CNR2 (0.51) | CNR2L3MBTL1GAAKMT2AGLA | |
| SCHEMBL1881450 | 0.70 | CNR2 (0.54) | CNR2L3MBTL1KMT2AGLAIRAK4 | |
| SCHEMBL22175937 | 0.69 | CNR2 (0.42) | CNR2L3MBTL1GAAKMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358919-B2 | Antibacterial compounds | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2025-07-15 | — | — | US | disclosed |
| US-20220235059-A1 | ANTIBACTERIAL COMPOUNDS | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2022-07-28 | — | — | US | disclosed |
| EP-3980418-A1 | ANTIBACTERIAL COMPOUNDS | Universita' Degli Studi di Siena (IT) | 2022-04-13 | — | — | EP | disclosed |
| WO-2020245759-A1 | ANTIBACTERIAL COMPOUNDS | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358919-B2 | Antibacterial compounds | ABCB11, CFTR, MRPL21 | CNR2 4529/4885L3MBTL1 4437/4885GAA 49/4885 |
| US-20220235059-A1 | ANTIBACTERIAL COMPOUNDS | ABCB11, CFTR, MRPL21 | CNR2 4529/4885L3MBTL1 4437/4885GAA 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.